Lexology November 22, 2024
Mintz

The PBM regulatory landscape continues to evolve at both the federal and state levels, making it critical for our clients involved in the PBM space to stay apprised of developments in the industry as they happen. Our team actively monitors these developments to provide you with this quarterly PBM Policy and Legislative Update. This update builds on prior issues and highlights federal and state activity from July, August, and September 2024. Activity in this space did slow down a bit over the summer as Congress and state legislators were in recess and stakeholders were generally focused on the election.

Federal Legislative Activity
House Committee on Oversight and Accountability Focuses on PBMs as the Cause of Rising Drug Costs. On July 23,...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Pharma, Pharma / Biotech
Advancing Cancer Care: The Role of Radiopharmaceuticals in Precision Medicine
Healthcare supply chain, pharmacy costs to rise in 2025: report
Insurer Denies Access To Drugs Granted Accelerated Approval By FDA
STAT+: DeepSeek signals China’s rising influence in AI — and AI drug development
Is 2025 the Chinese Year of BioPharma?

Share This Article